SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 107.42 |
| Enterprise Value ($M) | 81.05 |
| Book Value ($M) | 86.81 |
| Book Value / Share | 1.33 |
| Price / Book | 1.24 |
| NCAV ($M) | 84.73 |
| NCAV / Share | 1.29 |
| Price / NCAV | 1.27 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.47 |
| Return on Assets (ROA) | -1.10 |
| Return on Equity (ROE) | -1.47 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 13.65 |
| Current Ratio | 14.14 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 91.69 |
| Assets | 93.76 |
| Liabilities | 6.96 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ra Capital Management, L.p. | 1.20 | -87.73 | |
| 13G/A | Biotechnology Value Fund L P | 1.30 | -90.85 | |
| 13G/A | DAFNA Capital Management LLC | 1.37 | -19.43 | |
| 13G/A | Vanguard Group Inc | 6.24 | 0.00 | |
| 13G | BlackRock, Inc. | 6.20 | 0.00 | |
| 13G | Octagon Capital Advisors LP | 6.50 | ||
| 13G/A | Fmr Llc | 4.46 | 0.00 | |
| 13G | Deep Track Capital, LP | 9.99 | ||
| 13G | Vivo Opportunity Fund Holdings, L.P. | 7.70 | ||
| 13D/A | Growth Equity Opportunities V, LLC | 9.99 | 235.79 | |
| 13G/A | Victory Capital Management Inc | 5.71 | 35.91 | |
| 13G/A | Federated Hermes, Inc. | 19.90 | 3.83 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 37,341 | 139,682 | 26.73 | |
| 36,616 | 283,868 | 12.90 | |
| 41,022 | 235,625 | 17.41 | |
| 80,877 | 228,577 | 35.38 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RENB – Renovaro Inc. | REVB – Revelation Biosciences, Inc. |
| RGC – Regencell Bioscience Holdings Limited | RMTI – Rockwell Medical, Inc. |
| RNAZ – TransCode Therapeutics, Inc. |